- $3.31m
- $4.80m
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | n/a | ||
| Price to Tang. Book | n/a | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | n/a | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | n/a | ||
| Return on Equity | n/a | ||
| Operating Margin | n/a | ||
Financial Summary
| Year End 31st Mar | Unit | 2019 | 2020 | 2021 | 2022 | 2023 | 2024E | 2025E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $m | 3.45 | n/a | n/a | n/a | n/a | n/a | n/a | -100% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
GB Sciences, Inc. is a biopharmaceutical research and development company. The Company develops disease-targeted formulations of cannabis and other plant-inspired therapeutic mixtures for the prescription drug market through its wholly owned subsidiary, GbS Global Biopharma, Inc. (GBSGB). The Company's primary focus is on preparing its lead program for the treatment of the motor symptoms of Parkinson's disease (PD) in a human clinical trial. Through GBSGB, the Company is engaged in the research and development of plant-inspired medicines, with virtual operations in North America and Europe. GBSGB has a portfolio of intellectual property containing both plant-inspired formulations and its artificial intelligence (AI)-enabled drug discovery platform, as well as research contracts and various supplier arrangements. GBSGBs intellectual property covers a range of over 65 medical conditions, from which five drug development programs are in the preclinical stage of drug development.
Directors
- John Poss CHM (73)
- Andrea Small-Howard PRE (52)
- Zach Swarts CFO (33)
- Gary Henrie SEC
- Edmond Defrank IND (54)
- Last Annual
- March 31st, 2023
- Last Interim
- December 31st, 2023
- Incorporated
- May 2nd, 2018
- Public Since
- December 22nd, 2003
- No. of Shareholders
- 201
- No. of Employees
- 3
- Sector
- Biotechnology & Medical Research
- Industry
- Healthcare
- Exchange
Pink Sheets on Nasdaq- Shares in Issue
- 406,071,028
- Address
- 6450 Cameron St Ste 110A, LAS VEGAS, 89118-4337
- Web
- https://gbsciences.com/
- Phone
- +1 8888953594
- Auditors
- Assurance Dimensions
Upcoming Events for GBLX
Q1 2025 GB Sciences Inc Earnings Release
Q2 2025 GB Sciences Inc Earnings Release
Similar to GBLX
Acorda Therapeutics
Pink Sheets on Nasdaq
Actavia Life Sciences
Pink Sheets on Nasdaq
Acura Pharmaceuticals
Pink Sheets on Nasdaq
Adhera Therapeutics
Pink Sheets on Nasdaq
Ramoil Management
Pink Sheets on Nasdaq
FAQ
What is the GB Sciences share price?
As of Today at 21:00 UTC, shares in GB Sciences are trading at $0.01. This share price information is delayed by 15 minutes.
How has the GB Sciences share price performed this year?
Shares in GB Sciences last closed at $0.01 and the price had moved by +3.95% over the past 365 days. In terms of relative price strength the GB Sciences share price has underperformed the S&P500 Index by -12.76% over the past year.
What are the analyst and broker recommendations for GB Sciences?
There is no consensus recommendation for this security.
What is the GB Sciences dividend yield?
GB Sciences does not currently pay a dividend.
Does GB Sciences pay a dividend?
GB Sciences does not currently pay a dividend.
When does GB Sciences next pay dividends?
GB Sciences does not currently pay a dividend.
How do I buy GB Sciences shares?
To buy shares in GB Sciences you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
What is the market cap of GB Sciences?
As of the previous close price of $0.01, shares in GB Sciences had a market capitalisation of $4.81m.
Where are GB Sciences shares listed?
Here are the trading details for GB Sciences:
- Country of listing: United States
- Exchange: PNK
- Ticker Symbol: GBLX
What kind of share is GB Sciences?
Based on an overall assessment of its quality, value and momentum GB Sciences is currently classified as a Momentum Trap. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Is there a GB Sciences share price forecast for 2024?
We could not find analyst target price data for this security.
What is the trend in the GB Sciences share price?
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like GB Sciences. Over the past six months, its share price has outperformed the S&P500 Index by +78.85%.
As of the last closing price of $0.01, shares in GB Sciences were trading +59.4% higher than their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
What is the GB Sciences PE Ratio?
The GB Sciences PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at $0.01.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Who are the key directors of GB Sciences?
GB Sciences' management team is headed by:
- John Poss - CHM
- Andrea Small-Howard - PRE
- Zach Swarts - CFO
- Gary Henrie - SEC
- Edmond Defrank - IND